Drug Database
SO

sodium ferrous citrate (SCF, Eisai / Ferromia / Nemiffero)

✓ Approved

Eisai Co., Ltd. · 小分子 · 小分子

什么是 sodium ferrous citrate?

sodium ferrous citrate 是一种小分子,由Eisai Co., Ltd.研发。该药已获批,用于治疗相关适应症。

药物档案

商品名SCF, Eisai, Ferromia, Nemiffero
公司Eisai Co., Ltd.
药物类别小分子
状态Approved

治疗适应症

sodium ferrous citrate 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Blood and lymphatic system disordersAnaemia✓ Approved

相关研究文献

PubMedCancer & metabolism2026-11-19

Salidroside decreases lipid abundance, mitochondrial function, and expression of the mitochondrial citrate transporter SLC25A1 via miR-1343-3p in gastric cancer.

Cao Mingyuan M, Zhang Zhendong Z, Du Yuxin Y, Fang Jin J et al.

To investigate the potential mechanisms by which salidroside regulates mitochondrial function, SLC25A1 expression, and lipid abundance in gastric cancer (GC) cells via miR-1343-3p. Transcriptome sequencing was performed on MGC-803 cells before and after salidroside treatment to identify differentially expressed miRNAs and mRNAs. Bioinformatic analysis was then used to screen for candidate molecules. The interaction between miR-1343-3p and SLC25A1 was validated by dual-luciferase reporter assay, sequence alignment, and RNA immunoprecipitation (RIP). Mitochondrial morphology and function were examined by transmission electron microscopy and fluorescent probes. MGC-803 and AGS cells were used to assess the effects of salidroside, miR-1343-3p modulation, and SLC25A1 silencing on mitochondrial citrate export, lipid abundance, and cell proliferation. Furthermore, a nude mouse xenograft model was established to evaluate the effects of salidroside and a miR-1343-3p agomir on tumor growth, the expression of miR-1343-3p and SLC25A1, and tumor metabolic status. Transcriptome sequencing revealed 44 differentially expressed miRNAs and 1,384 differentially expressed mRNAs in MGC-803 cells following salidroside treatment. Among them, miR-1343-3p was significantly upregulated as a tumor-suppressive miRNA, while SLC25A1, a mitochondrial citrate transporter, was significantly downregulated. RT-qPCR and Western blot results demonstrated that salidroside significantly increased the expression of miR-1343-3p while decreasing the mRNA and protein expression of SLC25A1. Dual-luciferase reporter, sequence alignment, and RIP assays confirmed that miR-1343-3p directly targets SLC25A1. Further studies showed that salidroside treatment, miR-1343-3p overexpression, and SLC25A1 silencing could all cause the accumulation of mitochondrial citrate, reduced mitochondrial membrane potential, increased ROS production, and decreased the levels of NADH, ATP, acetyl-CoA, free fatty acids, cholesterol, and triglycerides, while significantly inhibiting GC cell proliferation. However, after knocking down miR-1343-3p, the opposite results were observed, which were efficiently rescued by salidroside. In vivo, both salidroside treatment and the miR-1343-3p agomir administration significantly reduced tumor volume and weight. Tumor tissues from these groups showed increased miR-1343-3p expression, decreased SLC25A1 expression, and lipid metabolic changes consistent with those observed in vitro. Salidroside inhibits GC cell proliferation and tumor growth by upregulating the tumor-suppressive miR-1343-3p, which directly targets and downregulates the mitochondrial citrate transporter SLC25A1. Meanwhile, decreased mitochondrial citrate export, impaired mitochondrial function, and reduced lipid abundance are observed. These findings indicate that miR-1343-3p and SLC25A1 may be promising therapeutic targets for metabolic intervention in gastric cancer.

PMID 43053216
阅读全文 →
PubMedBMC pediatrics2026-11-19

Comparative efficacy and safety of oral iron polymaltose complex vs. ferrous sulphate in the treatment of pediatric iron deficiency anemia: a systematic review, meta-analysis and trial sequential analysis.

Mubarika Moosa M, Farooq Omer O, Gardezi Syed Assar Imam SAI, Abdullah Muhammad M et al.

Oral iron supplementation is the first-line therapy for pediatric iron deficiency anemia (IDA). Ferrous sulphate (FS) remains the conventional standard of care but frequently induces gastrointestinal (GI) adverse effects. Iron polymaltose complex (IPC) has emerged as an alternative with improved tolerability, though its comparative efficacy remains debated. This systematic review and meta-analysis compared the efficacy and safety of oral IPC versus FS in the pediatric population. Electronic databases (PubMed, Embase, and Scopus) were systematically searched from inception to March 2026 for randomized controlled trials (RCTs) comparing oral IPC and FS in pediatric patients. The primary outcomes assessed were mean change from baseline in hemoglobin and serum ferritin levels, while secondary outcomes analyzed included mean change from baseline in serum iron and the incidence of gastrointestinal adverse effects. Pooled estimates were calculated using random-effects models. Certainty of evidence was graded via the GRADE framework, and Trial Sequential Analysis (TSA) evaluated the conclusiveness of primary outcomes. Eight RCTs involving 643 participants met the inclusion criteria. Meta-analysis demonstrated that FS achieved a significantly greater mean increase from baseline in hemoglobin (MD: -0.87 g/dL, 95% CI: -1.15 to -0.59, P < 0.00001) and serum ferritin levels (MD: -12.82 µg/L, 95% CI: -24.71 to -0.93, P = 0.03) compared to IPC. TSA confirmed that cumulative data for mean change in hemoglobin recovery reached sufficient statistical power, whereas ferritin data remained underpowered, highly heterogeneous ([Formula: see text]), and inconclusive. Primary pooled safety analyses revealed no statistically significant differences between IPC and FS in the risk of total adverse events (RR: 0.54, 95% CI: 0.10-2.97, P = 0.48) or diarrhea (RR: 0.51, 95% CI: 0.23-1.11, P = 0.09; [Formula: see text]). Secondary sensitivity modeling excluding active symptom solicitation suggested a lower overall burden of total adverse events for IPC. FS yields a greater mean increase in hemoglobin levels and iron store replenishment in pediatric IDA. Primary safety analyses demonstrate no clear evidence of a difference between IPC and FS regarding diarrhea risk or baseline overall adverse events. However, when accounting for methodological reporting variations across trials, sensitivity analysis suggests IPC may lower total adverse event rates in specific pediatric contexts.

PMID 43052861
阅读全文 →
PubMedBMC public health2026-11-19

Association of sodium intake with incident asthma and the modifying role of potassium: insights from a prospective study.

Huang Wufeng W, Hukportie Daniel Nyarko DN, Kang Jing J, Li Wen W et al.

Emerging evidence suggests that high dietary salt intake may contribute to the development of immune-mediated diseases, including asthma. However, the relationship between salt consumption and the risk of adult-onset asthma, as well as how it may be influenced by other dietary electrolytes, remains unclear. This study aimed to clarify the association between salt intake and asthma risk, with particular attention to the potential interaction with urinary potassium levels. We conducted a prospective cohort study of 373,647 adults from the UK Biobank who were free of asthma at baseline. Salt intake was evaluated using two complementary approaches: a subjective measure based on the self-reported frequency of adding salt to foods, and an objective estimate of 24-h sodium excretion derived from spot urine samples. Urinary potassium levels were also measured from spot urine samples and used as an indicator of potassium status. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between salt intake and asthma incidence, adjusting for multiple potential confounding factors, and to assess potential effect modification by spot urinary potassium concentrations. Over a median follow-up period of 15.4 years, we documented 10,511 incident asthma cases. Compared with those who never or rarely added salt, participants who reported always adding salt had a 27% higher risk of asthma (HR 1.27, 95% CI 1.17-1.38). Each 1-g/day increase in estimated 24-h sodium excretion was associated with a 15% higher asthma risk in men and a 39% higher risk in women. Spline analyses further showed a progressively increasing asthma risk with higher estimated 24-h sodium excretion, with a notably steeper gradient at lower spot urinary potassium concentrations and a modest attenuation at higher levels, supporting a potential sodium-potassium interaction in relation to asthma risk (P for interaction < 0.05). In this large cohort study, both self-reported high salt-adding habits and higher estimated 24-h sodium excretion were associated with an increased incidence of asthma. Notably, higher spot urinary potassium concentrations appeared to attenuate the adverse effects of high sodium on asthma risk, suggesting that a combined dietary strategy of reducing salt intake while maintaining adequate potassium may help lower the risk of adult-onset asthma.

PMID 43052935
阅读全文 →
PubMedJournal of the American Chemical Society2026-11-19

Machine Learning-Driven Electrolyte Additive Discovery for Ultrafast Charging of Sodium Metal Batteries.

Ye Yuanchang Y, Cheng Li L, Zou Minyi M, Dong Yingxia Y et al.

Sodium metal batteries hold immense promise for large-scale, high-power storage systems, yet their fast charging is severely constrained by sluggish Na+ transport across unstable electrode-electrolyte interphases. Conventional fluorine-donating additives suffer from inefficient self-decomposition, inevitably generating resistive organic byproducts. Herein, we propose an active machine learning framework based on Gaussian process regression to develop an innovative additive-triggered anion decomposition pathway. Guided by iterative screening of key physicochemical descriptors, a trace-level (0.02 M) sodium chlorodifluoroacetate (NaCDFA) additive is successfully identified. Theoretical calculations combined with in situ characterizations reveal that the NaCDFA thermodynamically promotes the targeted and continuous decomposition of the PF6- anion, enabling the construction of robust and highly conductive NaF-rich interphases, which substantially reduces the Na+ migration barrier. Consequently, the Na||Na3V2(PO4)3 cell achieves ultrastable cycling over 50,000 cycles at an extreme rate of 200 C. Furthermore, outstanding performance is retained under rigorous practical conditions, including high-mass-loading cathodes and limited sodium excess or anode-free architectures. This work establishes a cost-effective trace-level electrolyte additive strategy for engineering fast-charging interphases, and demonstrates the transformative potential of machine learning-guided materials discovery for advancing battery technology.

PMID 43053434
阅读全文 →
PubMedBMC nephrology2026-11-19

Correction: Characteristics of sodium and water retention in rats with nephrotic syndrome induced by puromycin aminonucleoside.

Xu Zaiping Z, Wang Yunlai Y, Feng Ye Y, Yang Mo M et al.

PMID 43052858
阅读全文 →
PubMedBioscience reports2026-11-19

Retraction: RNA-Seq analysis reveals critical transcriptome changes caused by sodium butyrate in DN mouse models.

Yang Hansen H, Zhang Zheng Z, Peng Rui R, Zhang Luyu L et al.

PMID 43053622
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多sodium ferrous citrate